Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29738304 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2DPP4HDAC1HDAC8MTNR1A | |
| SCHEMBL28674890 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2DPP4HDAC1HDAC8MTNR1A | |
| SCHEMBL25634556 | 0.88 | NPSR1 (0.34) | SMN1; SMN2DPP4HDAC1HDAC8TSHR | |
| SCHEMBL29738303 | 0.88 | NPSR1 (0.34) | SMN1; SMN2DPP4HDAC1HDAC8TSHR | |
| SCHEMBL31011123 | 0.87 | DPP4 (0.33) | SMN1; SMN2DPP4HDAC1HDAC8 | |
| SCHEMBL13780954 | 0.84 | DPP4 (0.36) | SMN1; SMN2DPP4HDAC1HDAC8DGAT2 | |
| SCHEMBL28761633 | 0.83 | DPP4 (0.36) | SMN1; SMN2DPP4HDAC1HDAC8DGAT2 | |
| SCHEMBL30136598 | 0.83 | MTNR1A (0.38) | SMN1; SMN2DPP4MTNR1AMTNR1BRORC | |
| SCHEMBL2853339 | 0.83 | MTNR1A (0.38) | SMN1; SMN2DPP4MTNR1AMTNR1BRORC | |
| SCHEMBL2853346 | 0.83 | MTNR1A (0.38) | SMN1; SMN2DPP4MTNR1AMTNR1BRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2381772-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | CHIRAL QUEST INC (US) | 2016-08-24 | — | — | EP | claimed |
| US-20230174461-A1 | METHOD FOR PREPARING CHIRAL 4-ARYL-ß-AMINO ACID DERIVATIVE | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230174461-A1 | METHOD FOR PREPARING CHIRAL 4-ARYL-ß-AMINO ACID DERIVATIVE | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2023-06-08 | — | — | US | disclosed |
| CN-113636950-B | Preparation method of chiral 4-aryl-beta-amino acid derivative | 浙江医药股份有限公司新昌制药厂 | 2023-01-17 | — | — | CN | disclosed |
| WO-2022188501-A1 | METHOD FOR RECYCLING DEGRADED WASTE OF ACETYL MELDRUM'S ACID DERIVATIVE | 台州市生物医化产业研究院有限公司 | 2022-09-15 | — | — | WO | disclosed |
| CN-114644568-A | Purification method of sitagliptin intermediate | 浙江医药股份有限公司新昌制药厂 | 2022-06-21 | — | — | CN | disclosed |
| CN-113636950-A | Preparation method of chiral 4-aryl-beta-amino acid derivative | 浙江医药股份有限公司新昌制药厂 | 2021-11-12 | — | — | CN | disclosed |
| US-10189760-B2 | Method for preparing sitagliptin intermediate via asymmetrical reduction method | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2019-01-29 | — | — | US | disclosed |
| US-9873651-B2 | — | — | 2018-01-23 | — | — | US | disclosed |
| US-9873651-B2 | — | — | 2018-01-23 | — | — | US | disclosed |
| US-20170305822-A1 | METHOD FOR PREPARING SITAGLIPTIN INTERMEDIATE VIA ASYMMETRICAL REDUCTION METHOD | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-10-26 | — | — | US | disclosed |
| EP-3156391-A1 | METHOD FOR PREPARING SITAGLIPTIN INTERMEDIATE VIA ASYMMETRICAL REDUCTION METHOD | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2017-04-19 | — | — | EP | disclosed |
| EP-2381772-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | CHIRAL QUEST INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8278486-B2 | Process and intermediates for the preparation of N-acylated-4-aryl beta-amino acid derivatives | CHIRAL QUEST, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278486-B2 | Process and intermediates for the preparation of N-acylated-4-aryl beta-amino acid derivatives | CHIRAL QUEST, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278486-B2 | Process and intermediates for the preparation of N-acylated-4-aryl beta-amino acid derivatives | CHIRAL QUEST, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100280245-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | CHIRAL QUEST, INC. | 2010-11-04 | — | — | US | disclosed |
| US-20100280245-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | CHIRAL QUEST, INC. | 2010-11-04 | — | — | US | disclosed |
| US-20100280245-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | CHIRAL QUEST, INC. | 2010-11-04 | — | — | US | disclosed |
| WO-2010078440-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | CHIRAL QUEST, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174461-A1 | METHOD FOR PREPARING CHIRAL 4-ARYL-ß-AMINO ACID DERIVATIVE | ENPEP, BCAT2, BCAT1 | SMN1; SMN2 3645/4885DPP4 330/4885HDAC1 3683/4885 |
| US-20170305822-A1 | METHOD FOR PREPARING SITAGLIPTIN INTERMEDIATE VIA ASYMMETRICAL REDUCTION METHOD | DPP4, DPP7, SI | SMN1; SMN2 1689/4885DPP4 1/4885HDAC1 695/4885 |
| US-20100280245-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | NR4A3, GRIA3, NR2C2 | SMN1; SMN2 3062/4885DPP4 3380/4885HDAC1 601/4885 |
| US-10189760-B2 | Method for preparing sitagliptin intermediate via asymmetrical reduction method | DPP4, DPP7, SI | SMN1; SMN2 1689/4885DPP4 1/4885HDAC1 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.